TYK2 Inhibition: Evolving Options in Psoriasis Care - Episode 9

Opportunities for TYK2 Inhibition in Moderate Psoriasis

Published on: December 19, 2025

Christopher G. Bunick, MD, PhD, April W. Armstrong, MD, MPH

Panelists discuss the questions below in this video. How do you see emerging TYK2 inhibitors, such as zasocitinib and ESK-001, fitting into the psoriasis treatment landscape, if approved? Building on IMMpulse findings that earlier biologic use in moderate psoriasis can improve outcomes, what opportunities do you see for TYK2 inhibitors to be used earlier in appropriate patients?

EP. 1: Cytokine Pathways and Their Impact on Plaque Psoriasis

EP. 2: Current Standard of Care and Treatment Options in Psoriasis

EP. 3: Role of Mechanisms of Action in Treatment Decisions and Personalized Care in Psorias

EP. 4: Challenges with Current Psoriasis Therapies

EP. 5: Therapeutic Potential of TYK2 Inhibition in Psoriasis

EP. 6: Selectivity of TYK2 Inhibition in Psoriasis

EP. 7: Understanding the FDA-Approved TYK2 Inhibitor in Psoriasis

EP. 8: Efficacy and Safety of Zasocitinib in Psoriasis and the Ideal Candidates for TYK2 Inhibitors

Now Viewing

EP. 9: Opportunities for TYK2 Inhibition in Moderate Psoriasis

EP. 10: Other Emerging TYK2 Inhibitors in Psoriasis

Panelists discuss the questions below in this video.
How do you see emerging TYK2 inhibitors, such as zasocitinib and ESK-001, fitting into the psoriasis treatment landscape, if approved? Building on IMMpulse findings that earlier biologic use in moderate psoriasis can improve outcomes, what opportunities do you see for TYK2 inhibitors to be used earlier in appropriate patients?